Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/49438
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFazekas, Franz-
dc.contributor.authorBajenaru, Ovidiu-
dc.contributor.authorBerger, Thomas-
dc.contributor.authorHojs Fabjan, Tanja-
dc.contributor.authorLedinek, Alenka Horvat-
dc.contributor.authorJakab, Gábor-
dc.contributor.authorKomoly, Samuel-
dc.contributor.authorKobys, Tetiana-
dc.contributor.authorKraus, Jörg-
dc.contributor.authorKurca, Egon-
dc.contributor.authorKyriakides, Theodoros-
dc.contributor.authorLisý, Lubomír-
dc.contributor.authorMilanov, Ivan-
dc.contributor.authorNehrych, Tetyana-
dc.contributor.authorMoskovko, Sergii-
dc.contributor.authorPanayiotou, Panayiotis-
dc.contributor.authorJazbec, Saša Šega-
dc.contributor.authorSokolova, Larysa-
dc.contributor.authorTaláb, Radomír-
dc.contributor.authorTraykov, Latchezar-
dc.contributor.authorTurcáni, Peter-
dc.contributor.authorVass, Karl-
dc.contributor.authorVella, Norbert-
dc.contributor.authorVoloshyná, Nataliya-
dc.contributor.authorHavrdová, Eva-
dc.date.accessioned2019-12-05T14:47:47Z-
dc.date.available2019-12-05T14:47:47Z-
dc.date.issued2013-
dc.identifier.citationFazekas, F., Bajenaru, O., Berger, T., Hojs Fabjan, T., Horvat Ledinek, A., Jakab, G., ... & Kyriakides, T. (2013). How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?. Frontiers in Neurology, 4(10), 1-14.en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar/handle/123456789/49438-
dc.description.abstractMultiple sclerosis (MS) is a neurological disorder characterized by inflammatory demyelination and neurodegeneration in the central nervous system. Until recently, disease-modifying treatment was based on agents requiring parenteral delivery, thus limiting long-term compliance. Basic treatments such as beta-interferon provide only moderate efficacy, and although therapies for second-line treatment and highly active MS are more effective, they are associated with potentially severe side effects. Fingolimod (Gilenya®) is the first oral treatment of MS and has recently been approved as single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis (RRMS) for adult patients with high disease activity despite basic treatment (beta-interferon) and for treatment-naïve patients with rapidly evolving severe RRMS. At a scientific meeting that took place in Vienna on November 18th, 2011, experts from ten Central and Eastern European countries discussed the clinical benefits and potential risks of fingolimod for MS, suggested how the new therapy fits within the current treatment algorithm and provided expert opinion for the selection and management of patients.en_GB
dc.language.isoenen_GB
dc.publisherFrontiers Research Foundationen_GB
dc.rightsinfo:eu-repo/semantics/openAccessen_GB
dc.subjectMultiple sclerosis -- Case studiesen_GB
dc.subjectMultiple sclerosis -- Treatmenten_GB
dc.subjectAlgorithmsen_GB
dc.titleHow does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?en_GB
dc.typearticleen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holderen_GB
dc.description.reviewedpeer-revieweden_GB
dc.identifier.doi10.3389/fneur.2013.00010-
dc.publication.titleFrontiers in Neurologyen_GB
Appears in Collections:Scholarly Works - FacM&SMed



Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.